Key clinical point: Ixekizumab is safe and effective through 4 years for treating psoriasis.
Major finding: “The proportion of patients achieving PASI 75/90/100 at week 204 using mNRI method were 82.8%, 66.4% and 48.3%, respectively,” noted the study investigators. There were no new safety concerns over the course of 4 years.
Study details: This phase 3 study of 1,346 was randomized, double-blind, and multicenter. Patients received placebo, ixekizumab (every 2 or 4 weeks), or etanercept (twice weekly) for moderate-to-severe plaque psoriasis. During week 12, all patients switched to Ixekizumab, and at week 60 patients could receive dose adjustments.
Disclosures: This study was funded by Eli Lilly and Company. Several investigators receive research funds, have consulting relationships, or are employees of the company.
Lebwohl MD, et al. J Eur Acad Dermatol Venereol. 2019 Sep 3. doi: 10.1111/jdv.15921. [Epub ahead of print].